NCT00674219View on ClinicalTrials.gov

Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder

PHASE3CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

May 31, 2005

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Obsessive-Compulsive DisorderGeneralized Anxiety Disorder
Interventions
DRUG

Memantine

Namenda 10mg BID for 12 weeks

Trial Locations (1)

90095

UCLA, Los Angeles

All Listed Sponsors
collaborator

Saban Family Foundation

OTHER

lead

University of California, Los Angeles

OTHER

NCT00674219 - Memantine Treatment for Obsessive-compulsive Disorder and Generalized Anxiety Disorder | Biotech Hunter | Biotech Hunter